Does Medicare cover Wegovy in 2026?

Where things actually stand right now

Three separate realities are sitting on top of each other, and mixing them up is the single biggest source of confusion. First, the underlying law hasn't moved: Medicare Part D is still barred from paying for a weight-loss drug just because someone wants to lose weight. Second, a much older and narrower exception has existed since March 2024, letting Wegovy through when it's prescribed for a specific heart-related reason rather than for weight loss. Third, and newest, a temporary $50-a-month scheme launched on 1 July 2026 that sidesteps the weight-loss exclusion altogether, but only for a limited time and only where a plan has opted in. None of these three things replaced the others. They stack.

Why Medicare excludes weight-loss drugs at all

When Congress built Part D in 2003, it borrowed a list of drug categories that state Medicaid programmes are allowed to exclude from coverage, and wrote that same list into Part D's rules under Section 1860D-2(e)(2)(A) of the Social Security Act. One entry on that list covers "agents when used for anorexia, weight loss, or weight gain." CMS confirmed in 2008 regulations that this applies even when the weight-loss use isn't cosmetic, obesity included. That's the entire legal basis for a drug like Wegovy being refused when the stated reason is weight management: it isn't a judgement about whether the drug works, it's a category exclusion baked into the statute itself.

The 2024 proposal that could have changed everything, and didn't

In November 2024, under the outgoing administration, CMS proposed reinterpreting that exclusion so obesity itself would count as a disease worthy of treatment, rather than something drugs are merely used "for weight loss" to manage. The agency estimated it could extend Part D and Medicaid coverage to roughly 3.4 million more people. It was, by most accounts, the biggest potential change to obesity-drug access in Medicare's history.

It didn't happen. When CMS published its final rule for contract year 2026 in April 2025, it declined to finalise the anti-obesity medication provisions, citing Executive Order 14192, "Unleashing Prosperity Through Deregulation," and calling the change "not appropriate at this time." Trade reporting since then suggests CMS may revisit the question later, pending review of the drugs' benefits and cost, but no rule is pending and no timeline has been announced. If you've read that Medicare "now covers Wegovy for obesity" because of the 2024 proposal, that claim is out of date. The proposal is dead for now, not delayed.

The genuine loophole: cardiovascular risk reduction

This is the one part of the story that's easy to get right, and worth explaining carefully because it's the actual, working route to coverage today. In March 2024, the FDA approved Wegovy to reduce the risk of major cardiovascular events, specifically heart attack, stroke, and cardiovascular death, in adults who already have established cardiovascular disease and who are living with obesity or are overweight. Because that use exists to protect the heart rather than to shed weight, CMS treats it as falling outside the weight-loss exclusion, and Part D plans can cover it.

The catch is in the paperwork, not the pharmacology. Coverage depends on the diagnosis code and clinical documentation submitted with the prior authorization request genuinely reflecting cardiovascular disease as the reason for the prescription, not obesity or weight management. A plan reviewing the request is checking that the record matches the FDA-approved indication, not simply that a cardiologist signed the script.

“An estimated 7% of Medicare beneficiaries, or 3.6 million overall, had established cardiovascular disease and obesity or overweight in 2020.”

That's a meaningful slice of the Medicare population who could plausibly qualify through the cardiovascular pathway alone, well before either the failed 2024 proposal or the new bridge programme entered the picture.

The new wrinkle for 2026: the Medicare GLP-1 Bridge

The most recent development is the Medicare GLP-1 Bridge, a temporary demonstration that started on 1 July 2026 and is due to run through 31 December 2027. Built under CMS's Section 402 demonstration authority rather than a permanent change to Part D's formulary rules, it lets eligible enrollees access certain GLP-1 drugs, including Wegovy, Zepbound, and the newer oral drug Foundayo, for a flat $50 monthly copay when used to reduce excess body weight, provided they meet prior authorization criteria and their plan has chosen to participate. It sits alongside a broader initiative, the BALANCE Model, whose Medicaid component is rolling out from May 2026, but whose Part D piece has been pushed back indefinitely, with the Bridge extended to cover the gap.

It's worth being precise about what this is and isn't. It is not a repeal of the statutory weight-loss exclusion, and it is not automatic: participation is voluntary for Part D plans, and eligibility still runs through prior authorization. It's best understood as a time-limited, opt-in pressure valve that CMS built while the underlying legal and political question remains unresolved, not the ending to this story.

Two requests, two outcomes: an illustrative example

These two scenarios are illustrative composites, not real people, but they show how the same drug produces opposite results depending on the paperwork behind it.

A 68-year-old with a documented history of coronary artery disease and a BMI of 31 sees a cardiologist, who prescribes Wegovy specifically to reduce the risk of a further cardiac event, and submits the request coded to atherosclerotic cardiovascular disease with obesity as a secondary factor. The plan approves it within its standard prior authorization window, because the record matches the FDA's cardiovascular indication precisely.

A 58-year-old with no diagnosed heart disease and a BMI of 33 asks their primary care physician for Wegovy to lose weight. The prescriber submits the request coded to obesity, with weight management stated as the reason. The plan declines it, citing the statutory exclusion, and the enrollee's plan happens not to participate in the GLP-1 Bridge, so the temporary $50 pathway isn't available to them either. Nothing about the drug changed between the two cases; the diagnosis and documented reason did.

Will Medicare ever cover Wegovy for weight loss outright?

Nobody can answer that with certainty, and it's worth being honest about that rather than guessing. KFF has estimated the ten-year cost of covering anti-obesity medications broadly could run to $25 to $35 billion for Medicare alone, a number that shapes political appetite as much as any clinical argument. The administration cited deregulation policy, not the drugs' effectiveness, when it dropped the 2024 proposal, and trade press reports CMS may reconsider later depending on further review of costs and benefits. The GLP-1 Bridge shows CMS is willing to experiment with narrower, time-limited access rather than a permanent rule change. Whether that becomes a stepping stone to broader coverage, or simply expires in December 2027, is genuinely unsettled, and anyone claiming otherwise is speculating past what the record supports.

This article is general information, drawn from CMS filings and health-policy reporting, not medical advice or a guarantee of coverage. Every plan applies its own prior authorization criteria, so confirm your specific situation with your prescriber and your Part D plan before assuming any outcome.